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ones or DPP-4 was associated with reduced risks for cardiovascular events (hazard 
ratio, 0.69; 95% CI, 0.57 to 0.84; P< 0.001 and hazard ratio, 0.71; 95% CI, 0.60 to 0.84; 
P< 0.001, respectively). ConClusions: Among patients with type 2 diabetes who 
were initiating oral diabetes drugs, metformin use was significantly associated with 
a decreased risk of major adverse cardiovascular events. And, the addition of thiazo-
lidinediones or DPP-4 inhibitors vs sulfonyurea on metformin was associated with 
a decreased cardiovascular risk.
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objeCtives: As the effects of statin use on type 2 diabetes mellitus (T2D) are not 
clearly determined, this study evaluated the risk of T2D as well as the benefit of 
cardiovascular disease in the relationship with statin use. Methods: We identi-
fied 5,441071 patients who were eligible for statin therapy and aged 40 years and 
older among National Health Insurance Examinees between January 1, 2005, and 
December 31, 2012. We evaluated the clinical impact of statin use on primary and 
secondary outcome. In addition, we compared the effect of duration or intensity of 
statin use. The primary outcome was new-onset T2D and the secondary outcomes 
included a composite of cardiovascular death, myocardial infarction or stroke, and 
all-cause death. Outcome data were linked with the national claims data of hospital 
admissions and national vital statistics through December 31, 2014. Propensity-
score matching was used to assemble a cohort of patients with similar baseline 
characteristics. Results: A total of 332,449 patients met the inclusion criteria, of 
whom 23,970 (7.21%) used statin therapy. Among them, 23082 pairs was matched 
by propensity-score method, with the consideration of baseline demographic, 
clinical characteristics, comorbidities, and concomitant cardiovascular medication 
factors. ConClusions: The final results of the primary and secondary study out-
comes will be available at ISPOR 18th Annual Euroepan Congress. This large-scale, 
population-based observational study lined with national claim data will provides 
a critical appraisal of effectiveness on new-onset of type 2 diabetes mellitus as well 
as cardiovascular events of statin use.
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objeCtives: Hypertriglyceredemia (HTG) is reported to be associated with acute 
pancreatitis (AP) as an etiological factor and an epiphenomenon. However, evidence 
to establish underlying correlation between TG levels and AP severity is not well 
established. This review was designed to analyse the correlation between acute pan-
creatitis (AP) and increased triglyceride (TG) levels thus defining the etiological role 
of elevated TG levels in AP patients. Methods: A comprehensive search strategy 
was developed and a systematic literature search in Pubmed and EMBASE from 1996 
to June 1, 2015 was carried out to identify studies mentioning triglycerides (TG) and 
acute pancreatitis (AP). Studies were screened using pre-defined inclusion criteria 
after which data from included trials were extracted, by two independent review-
ers and disagreements resolved by a third reviewer. The data was extracted into a 
data extraction form by one reviewer and a thorough quality check was performed 
by the other independent reviewer. Results: Of the 3,797 identified abstracts, 54 
unique studies were included in this review. The majority of the studies reported 
hypertriglyceridemia as an etiology of AP. Only four studies indicated a quantitative 
correlation between elevated TG levels and risk of AP. Amongst these studies, higher 
risk of AP among patients with moderate (150 to 499 mg/dL) and severe HTG (≥ 500 
mg/dL) was reported. Burden of disease (hospital length of stay and mortality) was 
significantly higher in the HTG-induced AP patients than other etiological forms of 
AP. ConClusions: There is paucity of a concrete body of evidence quantifying the 
role of TG levels and risk of AP. Randomized, placebo-controlled trials to determine 
role of TG in AP are highly desirable to substantiate the evidence gaps.
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objeCtives: Healthcare policy for reducing cardiovascular (CV) event burden 
should be guided by current and generalisable data. The objective of the study was 
to estimate 1-year CV event rates in a high-risk general population cohort in the 
UK. Methods: The UK THIN Database was utilised, with inclusion criteria of age 
≥ 18 years and evidence of a high-risk condition for CV events (prior CV disease 
[CVD], diabetes, or chronic kidney disease [CKD]) as of Jan 1, 2010 (index; initiation 
of follow-up). Both treated and untreated patients were included. Patient subgroups 
within CVD were: acute coronary syndrome (ACS) ≤ 12 months pre-index; ACS 12-24 
months pre-index; history of ischaemic stroke; other coronary heart disease (CHD); 
and peripheral arterial disease (PAD). These subgroups were not mutually exclusive 
due to the potential of multiple CVD conditions. Other subgroups included diabetes 
without CVD, and CKD without CVD. One-year risk for the composite endpoint of 
ACS (myocardial infarction or unstable angina), coronary revascularisation, ischae-
mic stroke, and CV death (estimated as 62% of all-cause death based on published 
sources) was estimated via Kaplan-Meier (KM) analyses. Results: A total of 339,943 
individuals met inclusion criteria. Estimated 1-year event rates (%, based on KM 
analysis) for the composite endpoint were: ACS ≤ 12 months, 12.9 (95% CI 11.3-
objeCtives: Heart Fatilure (HF) has become a public health problem reaching epi-
demic levels especially for the elderly population. The objetive of this study was the 
description of patients with HF been treated (followed) in a primary care (PC) area 
in Madrid by the use of data extracted from electronic medical records. Methods: 
A retrospective study was carried out to follow a cohort of 224,320 patients (18yo or 
older visiting PC at least once in 2006) from 01/01/2006 to 12/31/2010. Study outcomes: 
HF prevalent and incident cases, mortality of HF, time diagnosis to dead, GP, Nurse, 
cardiologist visit, hospitalizations and treatment (grouped by ATC-code). Results: 
HF prevalence during the period of study was 2.09% (4,680 patients), 63% women. Of 
these prevalent patients, 1,356 were diagnosed before 2006. The mean age of diagnose 
was 77.28 years (SD 11.52), 74.96 years for males (SD 11.53) and 78.65 (SD 11.29) for 
females. Incident cases during the study period was 3,324 (631 in 2006, 652 in 2007, 
677 in 2008, 703 in 2009 and 661 in 2010). 1,106 had at least one admisión to hospi-
tal. Average number of admisions 1.618 (SD 1.086). And 1028 patients died (22.61%). 
Average time from diagnosis to dead was 1,162 days (SD 1,064). The average yearly 
rate of visits per patient was 14.17 (SD 8.03) for GPs and 10.22 (SD 9.03) for Nurses, 
for consultant cardiologist was 0.10 (SD 0.16). The patients treatment mainly include 
Diuretics (72.93% of patients), Antithrombotic agents (70.96%), Agents acting on the 
renin-angiotensin system (69.89%), Calcium channel blockers (49.12%), Drugs used in 
diabetes (44.89%), Lipid modifying agents (44.17%), Cardiac therapy (38.29%) and Beta 
Blocking agents (37.63%). ConClusions: Despite the improvement of pharmacologi-
cal treatments and the better control of the cardiovascular risk factors. HF continues 
to be responsible for high mortality and a high resource consumption.
PCV49
inCidenCe of CaRdioVaSCUlaR eVentS following MyoCaRdial 
infaRCtion in fRanCe: an obSeRVational analySiS USing a ClaiMS 
databaSe
Philippe F1, Blin P2, Laurendeau C3, Bouee S4, Gourmelen J5, Levy Bachelot L6, Leproust S6, 
Steg PG7
1Département de Pathologie Cardiaque, Paris, France, 2INSERM CIC1401, ADERA, Bordeaux 
University, Bordeaux, France, 3Cemka-Eval, Bourg La Reine, France, 4CEMKA, Bourg La Reine, 
France, 5INSERM UMS 011, Villejuif, France, 6MSD France, COURBEVOIE, France, 7Département de 
Cardiologie, Paris, France
objeCtives: To describe the characteristics and treatment of patients having a 
myocardial infarction (MI) and estimate the incidence of cardiovascular events 
following the index MI, in the French Health Insurance database. Methods: A 
cohort of patients who had an MI in France between 2007 and 2011 was extracted 
from a claims database: the Echantillon Généraliste de Bénéficiaires (a 1% repre-
sentative sample of subjects covered by the general health insurance (≈600,000 
patients). The incidence of cardiovascular events following the index MI was esti-
mated using the Kaplan Meier method. A cox survival model aims to identify fac-
tors related to the composite outcome (death/MI/stroke). Results: 1,920 subjects 
were identified with an index MI: 2/3 were males, mean age= 67.2 y, 20.6% had 
diabetes, 37.6% hypercholesterolemia and 82.4% hypertension. Compared to the 
6 months preceding the index MI, rates of use of medications increased in the 
6 months following MI for statins (91.1%/30.7%), Aspirin+other antiplatelet agent 
(82.1%/7.1%), class III antiarrhythmics (8.4%/2.4%), oral anticoagulants (10.1%/5.1%), 
non thiazide diuretics (32.9%/19.1%), ACE-inhibitors (71%/18.6%), beta-blockers 
(86.0%/26.5%), and nitrates (46.4%/9.9%). Cumulative incidences at 1, 2 and 3 years 
after the index MI were: For deaths (all cause and including in-hospital death): 
17.8% (CI95%= 16.0%;19.5%), 21.6% (CI95%= 20.7%;23.5%), 27.0% (CI95%= 25.8%;29.1%); 
For MI (recurrence): 3.1% (CI95%= 2.3%;3.8%), 4.1% (CI95%= 3.2%;5.0%%), 4.7% 
(CI95%= 3.7%;5.7%); For stroke (or transit ischemic attack): 1.9% (CI95%= 1.3%;2.5%), 
3.1% (CI95%= 2.3%;3.9%%), 4.1% (CI95%= 3.1%;5.0%); For the composite outcome 
(death/MI/stroke) : 20.7% (CI95%= 18.9%;22.5%), 26.0% (CI95%= 24.0%;28.0%), 32.1% 
(CI95%= 29.8%;34.3%). A cox multivariate survival model identified the follow-
ing independent correlates of the composite outcome: age (ref < 60y) (60-70y: 
HR= 2.071 CI= [1.051;2.820], 70-80y: HR= 3.463 CI= [2.640;4.541], > 80y: HR= 7.124 
CI= [5.946;9.235]), diabetes (HR= 1.229,CI= [1.028;1.469]) percutaneous coronary inter-
vention (HR= 0.579,CI= [0.457;0.689]), and coronary artery bypass grafting (HR= 0.5
58,CI= [0.359;0.869] ConClusions: Despite high rates of prescription of medical 
therapy, all-cause mortality and CV event rates remained high following MI. This 
underscores the need to improve secondary prevention.
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objeCtives: The cardiovascular outcomes of oral antidiabetic drugs in type 2 diabe-
tes are still unknown. Methods: We identified 1,035,824 patients with type 2 who 
initiated oral antidiabetic drugs in Korea between January 1, 2005, and December 
31, 2011, using national claim data, and outcome data were linked with the national 
registries of hospital admissions and vital statistics. Our study evaluated the cardio-
vascular effects of metformin as initial pharmacotherapy and different second-line 
agents added on metformin. The primary outcome was a composite of cardiovas-
cular death, myocardial infarction, or ischemic stroke, and the follow-up was per-
formed through December 31, 2013 Results: Among 423,081 patients who are 
initiating oral antidiabetic drugs, 208,990 (49.4%) began diabetes treatment with 
metformin. During 3 years of follow-up, the adjusted risk of primary outcomes 
was significantly lower in the metformin user than in the metformin non-user 
(hazard ratio, 0.94; 95% CI, 0.91 to 0.97; P < 0.001). Among 157,509 patients who were 
requiring second-line agents add-on metformin, 123,830 (78.6%) used sulfonylureas, 
9,848 (6.3%) used thiazolidinediones, and 23,831 (15.1%) used dipeptidyl peptidase 
4 [DPP-4] inhibitors. Compared with sulfonyurea, the addition of thiazolidinedi-
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significantly increased from 18% to 25% with carvedilol and bisoprolol versus meto-
prolol tartrate. Our primary findings were consistent through various sensitivity 
analyses. ConClusions: We suggest that there is no evidence of a differential 
effect of β -blockers on mortality in older patients with HF, but the agent selected 
may have an impact on the rate of HF readmissions.
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objeCtives: Identifying the drivers of trends in mortality for disease classes is 
challenging. We used the Requiem model to visualise trends by gender and age in 
3-D format to identify cohort effects, impacts of interventions and mortality coding 
changes in specific cardiovascular diseases (CVD). Methods: The Requiem model 
analysed and smoothed ONS mortality statistics for England and Wales from 1970 
to 2013 by single year of age and gender. Disease codes were mapped at 4-digit 
level from ICD-8 to ICD-10 by medical modellers. An analysis was run for all CVD 
and individual diseases within that category. Outputs were displayed in multiple 
formats, including 3-D images of central mortality and deaths by age over time, 
and heat maps of absolute mortality improvement per disease and the component 
each disease contributed to all-cause mortality trends. Results: CVD mortality 
has declined by up to 8% per year in England and Wales, especially in the “golden 
cohort” born in the 1930s, as shown clearly in the heat maps. Mortality rates from 
ischaemic stroke have fallen precipitously by up to 10% per year in both genders, 
especially in the 80+ age group, as shown in the 3-D charts. This contributed up to 
0.4% absolute improvement in all-cause mortality prior to 1990. Mortality improve-
ment from myocardial infarction was up to 20% per year in both genders aged 
40 to 80, especially in the mid-1980s to 1990s, contributing up to 2% in absolute 
improvement in all-cause mortality in men in the mid-1980s and 1% in women in 
the early 1990s. ConClusions: The Requiem model 3-D visualisation shows the 
substantial improvement in mortality from CVD and all causes was largely driven by 
improvements in ischaemic stroke and MI in the golden cohort. In future years, as 
this cohort eventually dies, mortality improvement rates in CVD are likely to decline.
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objeCtives: To use a stochastic all-cause, cause of death mortality model to deter-
mine the risk of cardiovascular (CVD) mortality in smokers compared with non-
smokers in the UK allowing for competing causes of death. Methods: The Sonata 
Vivo model adjusts population baseline mortality for known risk factors to calculate 
the mean age of death and most likely causes of death for an individual, and has 
been validated against long-term cohorts in the UK and USA. We used the model to 
calculate the likely outcomes for a 50 year-old male who smokes no, 10 or 20 ciga-
rettes a day, with population average values for blood pressure, body-mass index, 
cholesterol and alcohol consumption. Results: The mean ages of death were 82.7 
years for the non-smoker, 78.7 years for a 10/day and 76.1 years for a 20/day smoker. 
At each year of life, smokers had a higher mortality from CVD than non-smokers. 
However, overall, there were fewer CVD deaths in smokers than non-smokers. This is 
an example of Simpson’s paradox, where an association between factors at a popu-
lation level may be the opposite for each subgroup in the population. Smokers have 
increased mortality from cancer and respiratory disease, and on average die of these 
at a younger age than those who eventually die of CVD. Smokers also have fewer 
years of life than non-smokers in which CVD deaths can occur. ConClusions: 
Smoking increases the risk of many diseases, which have their greatest impact at 
different ages. Smokers have lower overall risks of CVD death as they are more likely 
than non-smokers to have died of cancer before the peak age for CVD deaths. The 
real-world effect of interventions for smoking-related diseases will be influenced 
by this impact of competing causes of death.
CaRdioVaSCUlaR diSoRdeRS – Cost Studies
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objeCtives: Venous thromboembolism(VTE) which comprises deep vein 
thrombosis(DVT) and pulmonary embolism(PE) is associated with a significant health-
care burden. Currently, standard of care is parenteral low molecular weight heparin 
(enoxaparin) plus warfarin. Rivaroxaban is an oral anticoagulant that doesn’t require 
dose adjustment or routine coagulation monitoring, bringing an important advan-
tage for VTE treatment. The EINSTEIN clinical program of rivaroxaban showed that, 
overall, hospitalized patients who received initial treatment with rivaroxaban for DVT 
and PE had a significantly shorter length of stay compared to patients who received 
enoxaparin/VKA. Therefore, the aim of this study was to estimate the budget impact 
of rivaroxaban treatment for VTE in comparison with current practice. Methods: 
The BIM was developed with a 1-year time horizon. Eligible patients were estimated 
for the entire private health system population and for single health plan according to 
three profiles (big, medium and small size). Epidemiology data, drug costs and adverse 
events information were obtained from literature. Resource utilization was captured 
from literature and validated by an expert panel. Total costs of hospitalization and 
14.5); ACS 12-24 months, 7.0 (95% CI 5.8-8.2); ischaemic stroke, 7.8 (95% CI 7.2-8.5); 
other CHD, 5.0 (95% CI 4.9-5.1); PAD, 6.7 (95% CI 6.4-7.1); diabetes without CVD, 1.9 
(95% CI 1.9-1.9); CKD without CVD, 6.4 (95% CI 5.9-6.9). ConClusions: This study 
suggests that CV event rates continue to remain high in the UK general popula-
tion with CVD or CKD. Patients who experienced an ACS event during the past 12 
months and those with a history of ischaemic stroke are at a particularly elevated 
risk for recurrent events.
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objeCtives: Long-Term Care (LTC) service users with dementia show higher 
expenditure and association of care-needs level (CNL) deterioration. The aim of 
this study was to determine risk factors that are associated with death among 
elderly LTC service users in Japan. Methods: In a retrospective cohort study, we 
extracted data from all subjects who used LTC services with CNL ranging from 1 
to 5 in 2010 in Kyoto prefecture, Japan. Our sample consisted of 50,268 adults aged 
65 years and above in 2010 and who had given consent to linkage of their National 
Healthcare Insurance data with corresponding LTC insurance claims data. Dementia 
and death were defined according to the corresponding ICD-10 code. Logistic regres-
sion (LR) analysis was used to identify factors associated with death in June 2011. 
Furthermore, we developed and pruned a supervised learning approach using non-
parametric Classification and Regression Tree (CART) and Random Forest (RF), the 
algorithms of machine learning, to create risk factors for death. In order to avoid 
model over fitting, we did our sampling by 1 to 1 ratio. Finally, our samples consisted 
of 12,070 adults enrolled and set 70% as training dataset, 15% as testing dataset, 
and 15% as validation dataset. Results: The factors associated with death were 
hospitalization more than 30 days in one year, older age, the male sex, and higher 
CNL, facility care services/ home care services use, and new dementia diagnosis 
with an area under the curve (AUC) of 0.782. Similar results were observed in the 
supervised learning approach, which including CART and RF for death with an AUC 
of 0.7333 and 0.7623, respectively. ConClusions: When applied prudently, both 
LR and CART are suitable for the analysis of death prediction, and more research 
is required to investigate the factors that are related to long-term hospitalization 
among elderly.
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objeCtives: Few studies examined the course of functional recovery following 
rehabilitation in patients after intracerebral hemorrhage (ICH). The prediction of 
progressive increments in functional status is important for appropriate treatment 
planning and for setting rehabilitation goals. The aim of this study was to develop 
and validate a prognostication model to predict the functional status at discharge 
for ICH patients using a retrospective cohort data in the Korea. Methods: Data 
were collected on electronic medical record (EMR) referrals and brain computed 
tomography (CT) images from the National Rehabilitation Center (NRC) in Korea. 
Functional level was measured using the modified bathel index (MBI), recorded at 
admission and discharge. Factors considered for predictors associated with the MBI 
total score at discharge included patients’ clinical and imaging variables (ICH loca-
tion, ICH volume, mass effect due to hemorrhage etc) at the admission. Results: 
Five hundred twenty six patients aged 13 years or older (mean age: 57.2 years) who 
were discharged between November 15, 2006 and April 24, 2015, from NRC were 
retrospectively followed. Predictors of the total discharge MBI score included stand-
ing balance, cognitive function measured by the total score of Mini-Mental State 
Examination (MMSE), functional ambulation categories, muscle strength of left hip 
flexor, muscle strength of right knee extensor, presence of pneumonia, spasticity of 
right lower extremity, intraventricular hemorrhage score, abnormality of pain sense, 
aphasia, hemorrhage of brainstem, intracerebral hemorrhage volume, longitudinal 
sitting balance, mass effect due to hemorrhage. The adequacy of prediction was as 
measured by adjusted R2= 0.8013. ConClusions: The functional status prediction 
model performed well. Further studies should be planned to evaluate whether the 
model can be of practical use to physicians when attempting to set up an appropri-




udem, montreal, QC, Canada
objeCtives: To compare the effectiveness of ß-blockers for older patients follow-
ing a primary hospital admission for HF. Methods: We conducted a cohort study 
using Quebec administrative databases to identify patients who were prescribed the 
ß-blockers, carvedilol, bisoprolol or metoprolol tartrate after the diagnosis of HF. We 
characterize the patients by the type of ß-blocker prescribed at discharge of their 
first HF hospitalization. To control for differences among patient characteristics, a 
multivariate Cox proportional hazards model was used to compare the combined 
primary endpoint of all-cause mortality and HF readmission, its components, and 
cardiovascular mortality. Results: Of the 3609 patients with HF with a median fol-
low-up of 3.0 years, the crude annual mortality was 16.5% with metoprolol tartrate, 
15.7% with carvedilol, and 17.7% with bisoprolol. After controlling for covariates, 
we found that carvedilol (HR 0.94; 0.80-1.09) and bisoprolol (HR 1.05; 0.94-1.17) were 
not superior to metoprolol tartrate in improving survival. HF readmission rate was 
